Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05428215 · ClinicalTrials.gov registry record · Phase 4
Comparison of PKs of 17-Beta-Estradiol Via Sublingual Placement Versus Swallowing in Male-to-Female Transgender Patients
A Phase 4 study, sponsored by MaineHealth.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT05428215 is a Phase 4 study that was terminated before completion, run by MaineHealth. The registered enrollment target is 2 participants.
The verdict
NCT05428215, a Phase 4 study, was terminated before completion, sponsored by MaineHealth.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
This crossover study will investigate the pharmacokinetics of oral versus sublingual administration of 17-beta-estradiol in the trans-female population.
Interventions
- DRUG 17beta Estradiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-12-29 |
| Est. Completion | 2023-07-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05428215
The ClinicalTrials.gov registry entry for NCT05428215 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MaineHealth, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 17beta Estradiol is the first listed.
NCT05428215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05428215 about?
NCT05428215 is a clinical study titled "Comparison of PKs of 17-Beta-Estradiol Via Sublingual Placement Versus Swallowing in Male-to-Female Transgender Patients". This crossover study will investigate the pharmacokinetics of oral versus sublingual administration of 17-beta-estradiol in the trans-female population.
What is the current status of trial NCT05428215?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2022-12-29. Estimated completion is 2023-07-20.
What interventions are being tested in trial NCT05428215?
The interventions under investigation include: 17beta Estradiol (DRUG).
Who is sponsoring clinical trial NCT05428215?
This trial is sponsored by MaineHealth, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.